CRKL
CRKL (CRK like proto-oncogene, adaptor protein) is an SH2 and SH3 domain-containing member of the CRK family that may mediate the transduction of intracellular signals. It is a substrate of the BCR-ABL tyrosine kinase and has been linked to RAS and JUN kinase signalling. Browse Assay Genie's current range of CRKL research reagents below, or read on for the biology behind the target.
CRKL (CRK like proto-oncogene, adaptor protein), also described by UniProt as Crk-like protein, belongs to the CRK family. UniProt annotates it as a protein that may mediate the transduction of intracellular signals. It is built around SH2 and SH3 (src homology) domains, and HGNC places it in both the SH2 domain containing and SH3 domain containing gene groups. According to the NCBI Gene summary, CRKL has been shown to activate the RAS and JUN kinase signalling pathways and to transform fibroblasts in a RAS-dependent fashion.
CRKL is also a substrate of the BCR-ABL tyrosine kinase and plays a role in fibroblast transformation by BCR-ABL. The same summary notes that it may be oncogenic. For this reason, the CRKL protein is of interest to researchers studying oncogenic signalling, cellular transformation and the pathways that act downstream of BCR-ABL.
The human CRKL gene is located at 22q11.21 and encodes a protein of 303 amino acids with a calculated mass of about 33.8 kDa. The mouse and rat orthologs are both named Crkl, which allows the signalling roles described above to be examined in rodent systems. The previous HGNC name for the gene, v-crk avian sarcoma virus CT10 oncogene homolog-like, points to its relationship with the CRK family of oncogene-related adaptors. No alternative gene symbols are listed. The gene is catalogued under HGNC:2363, NCBI Gene 1399 and UniProt P46109.
CRKL is an SH2 and SH3 domain adaptor that may mediate the transduction of intracellular signals, making it a candidate node in signalling studies.
CRKL has been shown to activate the RAS and JUN kinase signalling pathways, which makes it relevant to work on these cascades.
CRKL is a substrate of the BCR-ABL tyrosine kinase and contributes to fibroblast transformation by BCR-ABL.
CRKL can transform fibroblasts in a RAS-dependent manner and may be oncogenic, supporting its study in transformation research.
UniProt states that CRKL may mediate the transduction of intracellular signals. The NCBI Gene summary adds that it has been shown to activate the RAS and JUN kinase signalling pathways and to transform fibroblasts in a RAS-dependent fashion. It is also a substrate of BCR-ABL.
No alternative gene symbols are listed. The previous HGNC name was v-crk avian sarcoma virus CT10 oncogene homolog-like, and UniProt names the protein Crk-like protein. The current HGNC name is CRK like proto-oncogene, adaptor protein.
The NCBI Gene summary says CRKL plays a role in fibroblast transformation by BCR-ABL and may be oncogenic. Orthologs named Crkl exist in mouse and rat; check the datasheet of any product for its validated reactivity.
Other CRK family adaptors, BCR-ABL partners and RAS and JUN kinase pathway proteins with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P46109; product specifications from Assay Genie datasheets.